Literature DB >> 10706559

Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver.

C C Paulusma1, M J Kothe, C T Bakker, P J Bosma, I van Bokhoven, J van Marle, U Bolder, G N Tytgat, R P Oude Elferink.   

Abstract

We have studied regulation of the multidrug resistance protein 2 (mrp2) during bile duct ligation (BDL) in the rat. In hepatocytes isolated after 16, 48, and 72 hours of BDL, mrp2-mediated dinitrophenyl-glutathione (DNP-GS) transport was decreased to 65%, 33%, and 33% of control values, respectively. The impaired mrp2-mediated transport coincided with strongly decreased mrp2 protein levels, without any significant changes in mrp2 RNA levels. Restoration of bile flow after a 48-hour BDL period resulted in a slow recovery of mrp2-mediated transport and protein levels. Immunohistochemical detection of the protein in livers of rats undergoing BDL showed strongly reduced mrp2 staining after 48 hours, which was initiated in the periportal areas of the liver lobule and progressed toward the pericentral areas after 96 hours. Immunofluorescent detection of mrp2 in livers of rats undergoing 48 hours of BDL revealed decreased staining accompanied by intracellular localization of the protein in pericanalicular vesicular structures. Within this intracellular compartment, mrp2 colocalized with the bile salt transporter (bsep) and was still active as shown by vesicular accumulation of the fluorescent organic anion glutathione-bimane (GS-B). We conclude that down-regulation of mrp2 during BDL-induced obstructive cholestasis is mainly posttranscriptionally regulated. We propose that this down-regulation is caused by endocytosis of apical transporters followed up by increased breakdown of mrp2, probably in lysosomes. This breakdown of mrp2 is more severe in the periportal areas of the liver lobule.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706559     DOI: 10.1002/hep.510310319

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

1.  Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer.

Authors:  Tatsuharu Yamada; Toshiyuki Arai; Masato Nagino; Koji Oda; Junichi Shoda; Hiroshi Suzuki; Yuichi Sugiyama; Yuji Nimura
Journal:  Langenbecks Arch Surg       Date:  2005-06-17       Impact factor: 3.445

2.  Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver.

Authors:  Daniel Y Hung; Gerhard A Siebert; Ping Chang; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 3.  Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport.

Authors:  Kousei Ito; Hiroshi Suzuki; Toshiharu Horie; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

4.  Hepatoprotection in bile duct ligated mice mediated by darbepoetin-α is not caused by changes in hepatobiliary transporter expression.

Authors:  Christian Eipel; Elena Menschikow; Michael Sigal; Angela Kuhla; Kerstin Abshagen; Brigitte Vollmar
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

Review 5.  Genetics of familial intrahepatic cholestasis syndromes.

Authors:  S W C van Mil; R H J Houwen; L W J Klomp
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

Review 6.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 7.  Dynamic localization of hepatocellular transporters in health and disease.

Authors:  Marcelo G Roma; Fernando A Crocenzi; Aldo D Mottino
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

8.  Bile acid analysis in biliary tract cancer.

Authors:  Jeong Youp Park; Byung Kyu Park; Jun Sang Ko; Seungmin Bang; Si Young Song; Jae Bock Chung
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

9.  Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.

Authors:  Markos Leggas; Masashi Adachi; George L Scheffer; Daxi Sun; Peter Wielinga; Guoqing Du; Kelly E Mercer; Yanli Zhuang; John C Panetta; Brad Johnston; Rik J Scheper; Clinton F Stewart; John D Schuetz
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

10.  Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis.

Authors:  Jin Chai; Shi-Ying Cai; Xiaocong Liu; Wei Lian; Sheng Chen; Liangjun Zhang; Xinchan Feng; Ying Cheng; Xiaochong He; Yu He; Lei Chen; Rongquan Wang; Huaizhi Wang; James L Boyer; Wensheng Chen
Journal:  J Hepatol       Date:  2015-07-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.